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The DAT is a test used to demonstrate in vivo antibody and/or
complement coating of RBCs. Typically, the DAT is performed in
test tubes; however, recently a number of commercially available
tests using gel-filled microtubes have become available. Few data
comparing the sensitivity of these test media are available. To
compare the rate of detection of a positive DAT performed in test
tubes versus in gel-filled microtubes and to assess the clinical
significance of the results in patients undergoing evaluation of
anemia, we tested 310 consecutive EDTA-anticoagulated blood
samples from adult patients. The samples were analyzed using both
the conventional tube technique and a gel-based assay (DiaMed®;
Cressier sur Morat, Switzerland). Test results were expressed as
either positive or negative. When a positive result by either
technique was encountered, the treating physician was interviewed
to determine whether the result warranted further patient
investigation or treatment. In 268 out of 310 cases the DAT was
negative by both methods. Of the 42 patients with a positive DAT,
the test was positive by both methods in 18 patients. In the
remaining 24 cases the DAT was positive by the gel test only. In all
cases positive by both techniques the test result affected patient
management. Of the 24 cases that were positive only by gel test, 3
were judged to be clinically significant. In this study, the gel test
was more sensitive than the tube technique for performance of the
DAT. However, the clinical significance of a DAT positive only by a
gel test is doubtful. We believe that use of the gel-based DAT should
be more extensively evaluated before it is adopted as a standard
technique in general clinical laboratory practice.
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The DAT is used to demonstrate in vivo antibody
and/or complement coating of RBCs. The principle of
this test was first demonstrated in 1908 when rabbit
erythrocytes, sensitized by goat anti-rabbit serum,were
stongly agglutinated by the subsequent addition of
rabbit anti-goat serum. However, it was not until 1945,
when Coombs showed that blood group antibodies
could be demonstrated in serum or on sensitized RBCs,
that the test was adopted by clinical laboratories.1 The
DAT is an essential test in the evaluation of autoimmune
hemolytic anemia (AIHA). The DAT also has importance
in the blood bank, where it is performed as part of the
evaluation of hemolytic transfusion reactions.
Typically, the DAT is performed in test tubes;
however, recently a number of commercially available
tests using gel-filled microtubes have become
available.2 Only limited data comparing the sensitivity
of these test media and their clinical relevance are
available.3,4 In this study, we compare the rate of
detection of a positive DAT performed in test tubes
versus in gel-filled microtubes and assess the clinical
significance of the results in patients undergoing
evaluation of anemia.
Mater ials and Methods
Patients and samples
We studied 310 consecutive blood samples sent to
our hospital’s Clinical Immunology laboratory for the
DAT. The samples were collected in EDTA-containing
tubes (Becton Dickinson and Co., UK) and were
analyzed, using both the conventional tube technique
and a gel-based assay, on the day of collection.
DAT—tube technique
DATs were performed by the classic tube
technique using polyspecific antihuman globulin
(AHG) serum (anti-IgG + anti-C3d; Gamma Biologicals,
Houston,Texas). In this technique, RBCs were washed
× 3 using NaCl 0.9% and resuspended to a 3–5% saline
suspension. Two drops of polyspecific AHG were
added to 1 drop of the washed cells, centrifuged for 1
minute at 900 × g, and examined macroscopically for
agglutination. Positive samples were further tested
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with monospecific anti-IgG (Gamma Biologicals) and
anti-IgA, -IgM, -C3c, and -C3d (DiaMed AG, Cressier sur
Morat, Switzerland). Agglutination reactions were
graded strongly positive (4+ and 3+), moderately
positive (2+ and 1+), and weakly positive (W+),
according to the manufacturer’s directions.
DAT—gel technique
Gel tests were performed by adding 50 µL of a 0.8%
RBC suspension in LISS (ID-Diluent 2) to the top of
each microtube in a LISS/Coombs ID card (DiaMed
AG). The cards were centrifuged at 910 rpm for 10
minutes, using the ID-Centrifuge 24S. All positive
results (presence of agglutinated RBCs in the gel
matrix) were re-examined using rabbit monospecific
anti-IgG, -IgM, and -C3d (DC-screening monospecific
Coombs sera, DiaMed AG). Negative reactions
appeared as a discrete cell button at the base of the
column.
Further investigation of positive DAT tests
When a positive DAT result was obtained by either
the tube or the gel technique, the treating physician
was interviewed by one of the investigators to
determine the patient’s diagnosis and whether the
result warranted further patient investigation or
treatment. In addition, laboratory data pertinent to
possible hemolysis were abstracted from the patients’
charts (serum bilirubin, lactate dehydrogenase [LDH],
and, when available, haptoglobin levels and
reticulocyte count). An isolated elevation of LDH was
not considered to be indicative of hemolysis because of
its lack of specificity for this diagnosis.
Statistical analysis
The sensitivity and specificity of the gel technique
was calculated, using a result of the tube test, to be
either truly positive or negative. From these
calculations, the positive and negative predictive values
were determined.
Results
Three hundred and ten samples were analyzed. Of
these, 268 (86%) were negative by both tube and gel
testing and 42 (14%) were postitive by at least one test
technique. Of the 42 positive samples, 21 (50%) were
positive by gel and negative by tube testing, 3 samples
(7%) were positive by tube testing and negative by gel
testing, and 18 (43%) were positive by both tube and
gel testing (Table 1).
Of the 18 samples that were positive using both
techniques, the IgG test only was positive in 11, while
in 7 samples both IgG and C3 were found on the RBCs.
No samples were positive for C3 only. Identical results
were obtained in tube and gel tests. Of the 21 samples
positive using gel testing only, 20 were positive for IgG
and 1 was positive for C3 only.
The sensitivity of the gel test compared to the tube
test using a polyspecific AHG reagent was 85 percent
and its specificity was 93 percent. When a monoclonal
IgG reagent was used, the sensitivity and specificity
were 95 percent and 93 percent, respectively. The
positive predictive value (PPV) of a positive gel test
using the polyspecific reagent was only 46 percent
while the negative predictive value (NPV) was 99
percent. For the monoclonal IgG reagent, the PPV and
NPV were 47 percent and 99 percent, respectively.
Clinical features of patients with a positive DAT
The clinical diagnoses of the patients with a
positive DAT by both gel and tube tests are listed in
Table 2. Of note is that in patients with a positive DAT
by tube and gel testing, the clinical diagnosis of most of
the patients is one known to be associated with a
positive DAT.
Laboratory parameters of patients with a positive
DAT
Of the 18 patients with a positive DAT by tube and
gel testing, 8 (44%) had at least 1 laboratory marker of
hemolysis. However, of the 21 patients with a positive
gel test only, 2 patients (9%) had positive hemolytic
Table 1 . Number of positive and negative DATs (using polyspecific AHG)
tests by tube and gel testing
Tube tests
Positive Negative Total
Positive 18 21 39
Gel tests Negative 3 268 271
Total 21 289 310
Table 2. Clinical diagnoses of patients with positive DATs by both tube
and gel techniques
Number of Patients Diagnosis
7 Chronic lymphocytic leukemia
3 Systemic lupus erythematosus
3 Immune thrombocytopenic purpura
1 Non-Hodgkins lymphoma
1 Monoclonal gammopathy
1 Hypersplenism,Hepatitis C positive
2 Unknown
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parameters while none of the patients with a tube-test-
only DAT had abnormal markers of hemolysis.
Effect of a positive DAT on further patient
investigation or treatment
In 94 percent of the 18 patients with a positive
DAT by tube and gel testing, the result elicited further
diagnostic or therapeutic action, while an isolated
positive gel test led to further diagnostic or therapeutic
activity in only 9 percent of cases. None of the patients
with a tube-test-only DAT had further tests performed
nor received any treatment based on the result of the
test.
Discussion
The use of gel-based microcolumn tests was
introduced into the blood bank laboratory at the end of
the 1980s for blood typing, antibody detection, and
DATs.5,6 Gel tests have grown in popularity because of
their increased accuracy and ease of use compared to
classic tube tests. Furthermore, gel tests require
smaller samples of RBCs and serum for testing, a
distinct advantage when testing newborn and
premature infants. Gel test systems also decrease the
exposure of laboratory staff to potentially hazardous
blood samples and breakable glassware. Finally, the test
result obtained using gel test cards remains stable for
up to 48 hours and can thus be saved for comparison
or consultation after the test has been performed.
A number of studies have been published
demonstrating the increased sensitivity of the gel test
compared to tube testing in detecting RBC
alloantibodies in patients’ sera.7,8 This increased
sensitivity permits the detection of alloantibodies that
would otherwise have remained undiagnosed, and has
been shown to have definite clinical value in
preventing potential hemolytic transfusion reactions in
a number of cases.9,10
Gel testing for the DAT compared to tube testing
has been studied to a lesser extent, and the clinical
relevance of a positive DAT by gel test is unknown.3,4,11
We performed the current study to determine the
sensitivity, specificity, and positive and negative
predictive values of one gel test (DiaMed) compared to
traditional tube testing, which until now has been
considered the standard test system. We also sought to
assess the immediate clinical relevance of a DAT
positive by either technique by determining the
treating physicians’ response to the test result in terms
of ordering further diagnostic tests or instituting
therapy based on the test result. Our results show that
of 42 samples positive by either technique using
polyspecific antihuman globulin, 18 (43%) were
positive by tube and gel testing, while 21 (50%) were
positive by gel testing only. Three samples (17%) were
positive by tube testing and negative by the gel test.
Thus the sensitivity of the gel test was 86 percent.
When monospecific reagents (anti-IgG and anti-C3)
were used, the sensitivity increased to 95 percent for
IgG and decreased to 78 percent for C3. These results
are similar to those of Tissot et al.,12 except that in their
study the sensitivity of the gel test using anti-C3 was
only 16 percent. This may be significant because it is
known that in patients with AIHA, hemolysis is more
severe when both C3 and IgG are present on the RBCs.
Our study has demonstrated that the gel test is
highly specific compared to the tube test: 93 percent
using polyspecific and anti-IgG reagents, and 99
percent using anti-C3. The results are concordant with
those of Tissot et al.,12 but differ from those of
Nathanlang et al.3 The latter group compared gel and
tube DAT tests in newborns with suspected fetal-
maternal ABO incompatibility and in adults with
known AIHA and found a sensitivity of 94 percent and
a specificity of 85 percent. When only the adults in the
study are considered, the sensitivity and specificity
were 100 percent and 80 percent, respectively. These
differences may be accounted for by the fact that
Nathanlang et al. studied a different patient population
than ours: all of their adult patients had known AIHA
and thus would be more likely to have a positive DAT
by any technique, compared to our patients,who were
undergoing an evaluation for anemia whose cause was
undetermined at the time of DAT testing. This
difference in patient population also explains the
lower PPV of the gel test in our study (46%) compared
to 94 percent among the adult patients in their study.
When we analyzed the clinical relevance of the
positive DAT, we noted that in 17 of the 18 patients
(94%) with a positive DAT by both techniques, the
result impacted clinical decision making. By contrast,
in only 2 of the 21 patients (9%) with a positive DAT by
gel testing only did the result lead to further relevant
clinical activity. A similar trend was found when
laboratory markers of hemolysis were examined in
patients with a positive DAT. When the DAT was
positive by both techniques, hemolytic parameters
were observed in 74 percent of patients, while only 9
percent of patients with a gel-only positive DAT had
other laboratory evidence of hemolysis.
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These results suggest that the gel test is more
sensitive than the conventional tube test for
performance of the DAT. The relatively low number of
patients with a gel-only positive test having clinical or
laboratory evidence for hemolysis suggests a high
falsely positive rate for the gel test. However, we
cannot exclude the possibility that some patients in
our study who had a positive gel test may develop
hemolytic anemia or another disease related to a
positive DAT in the future. Furthermore, in this study
we did not take into account the strength of
agglutination obtained in the gel test. This was
because, at the time that this study was performed, our
hospital’s immunology laboratory reported DAT test
results as“positive”or“negative”and we postulated that
treating physicians were likely to make clinical
judgements on this basis without considering the
strength of a positive test result.
In conclusion, we believe that aspects of the gel-
based DAT, such as the correlation of strength of
agglutination with evidence for hemolysis, should be
more extensively evaluated before it is adopted as a
standard technique in place of conventional tube
testing in general clinical laboratory practice.
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